Toward a more rational policy for autologous hematopoietic stem cell mobilization.
Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Steven.Devine@osumc.edu
Steven M
SM
Devine
D018952:Antigens, CD34 / Q000276:immunology; D001596:Benzylamines; D017326:Clinical Trials, Phase III as Topic; D000080027:Cyclams; D004338:Drug Combinations; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000191:economics / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000494:pharmacology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000276:immunology; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D001596:Benzylamines; C527276:CXCR4 protein, human; D000080027:Cyclams; D004338:Drug Combinations; D006571:Heterocyclic Compounds; D007155:Immunologic Factors; D019718:Receptors, CXCR4; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor